Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 40 peer-reviewed journal articles Updated
Pulmonology

Why Do COPD Flare-Ups Keep Happening? How to Prevent Them

At a Glance

Frequent COPD flare-ups can result from inhaler problems, missed doses, smoking, pollution, infections, or another condition such as heart failure or sleep apnea. Prevention usually combines a treatment review, trigger avoidance, vaccines, pulmonary rehabilitation, and a written action plan.

In this answer

4 sections

01

Reassessing Your Inhalers and Triggers

02

Strengthening Your Body and Mind

03

Looking Beyond COPD (Mimics and Overlaps)

04

Adjusting Your Medical Therapy

Living with repeated COPD exacerbations (flare-ups) can be frightening and frustrating, but having them does not necessarily mean you have done something wrong. Frequent exacerbations—often defined by guidelines as two or more moderate flare-ups, or at least one requiring hospitalization, in a single year [1] [2]—happen for a variety of reasons. These range from incorrect inhaler technique and continued exposure to triggers, to the presence of other medical conditions that mimic or complicate flare-ups [3] [4].

Preventing them requires a comprehensive reassessment: reviewing how you use your inhalers, avoiding environmental triggers, getting recommended vaccines, participating in pulmonary rehabilitation, and potentially adjusting your maintenance medications. Simply adding more medication isn’t always the answer—the goal is to uncover exactly why the flare-ups keep happening [3] [5].

When to Seek Emergency Care

Before discussing prevention, it is critical to know when a flare-up is a medical emergency. Do not wait for a routine appointment or try to manage at home if you experience:

  • Severe breathlessness at rest or an inability to speak in full sentences
  • A blue or gray tint to your lips or fingers
  • New confusion, agitation, or extreme drowsiness
  • Chest pain
  • Symptoms that rapidly worsen and do not respond to your prescribed rescue inhaler
    Seek immediate emergency medical attention if these occur.

Reassessing Your Inhalers and Triggers

Even the best COPD medication won’t work if it doesn’t reach your lungs. Studies show that a significant portion of patients hospitalized for COPD exacerbations make critical errors in their inhaler technique [6]. Proper technique depends on the specific device [7] [8]:

  • Dry-powder inhalers (DPIs) generally require a quick, deep, forceful breath to pull the powder out.
  • Metered-dose inhalers (MDIs) usually require a slow, steady breath and coordination, and they often work much better when used with an attachment called a spacer.

Ask a pharmacist or doctor to watch you use your specific device to ensure your technique is correct. Skipping doses of your daily maintenance inhalers also increases the risk of flare-ups [9] [10].

Preventing flare-ups also involves minimizing the external factors that irritate the lungs:

  • Quitting Smoking: Stopping smoking, with the help of counseling and medications, is one of the most effective steps you can take to prevent future exacerbations [11].
  • Reducing Air Pollution: Short-term exposure to outdoor air pollutants (like fine particulate matter, or PM2.5) and indoor pollutants (like fumes from heating or cooking) can trigger flare-ups [11] [12] [13]. Check local air quality alerts and improve indoor ventilation when possible.
  • Getting Vaccinated: Respiratory infections from viruses and bacteria are common exacerbation triggers [14]. Staying up to date on influenza (flu), pneumococcal, COVID-19, and (if eligible) respiratory syncytial virus (RSV) vaccinations can help prevent severe infections and lower your risk of hospitalization [15] [16] [17].

Strengthening Your Body and Mind

Medical care for COPD extends beyond inhalers. Rebuilding your physical strength and knowing how to respond to symptoms are proven ways to reduce the impact of flare-ups:

  • Pulmonary Rehabilitation: This supervised program combines exercise training, education, and emotional support. For people recovering from a severe flare-up, guidelines conditionally recommend starting a pulmonary rehab program within three weeks of leaving the hospital [18] [11]. It also provides a safe space to discuss the anxiety, depression, and fear of breathlessness that often accompany severe COPD.
  • Nutrition: COPD can significantly affect your weight, leading to either muscle wasting (cachexia) or obesity. Addressing your specific nutritional needs with a dietitian is an important part of managing the disease [19].
  • Written Action Plans: A customized written plan gives you a clear “green/yellow/red” guide to recognize early signs of a flare-up and tells you exactly when to start a rescue medication or call your doctor. When paired with supported education, action plans reduce the likelihood of hospital admissions [20]. Never self-start leftover antibiotics or oral steroids unless specifically instructed by your personalized action plan.

Looking Beyond COPD (Mimics and Overlaps)

While COPD flare-ups are common, they are not the only cause of acute shortness of breath. Other illnesses can coexist with COPD or mimic an exacerbation [4] [21]. If your flare-ups are unusually frequent or severe, your doctor will assess whether another condition is contributing to your symptoms:

  • Heart Failure: Heart problems can cause fluid buildup and breathlessness. Doctors may use heart ultrasounds or blood tests like BNP (brain natriuretic peptide) to check for this [22] [23].
  • Asthma Overlap: Some patients have features of both asthma and COPD, which significantly changes how they should be treated [24].
  • Bronchiectasis: This is an abnormal widening of the airways that leads to mucus buildup and recurrent infections [25].
  • Obstructive Sleep Apnea (OSA): Untreated sleep apnea is linked to a higher rate of COPD flare-ups and poorer outcomes [26] [27].
  • Pulmonary Embolism (PE): A blood clot in the lung (PE) can cause sudden shortness of breath. Doctors consider testing for PE if an episode of breathlessness is unusual or unexplained [28].

Adjusting Your Medical Therapy

If you are using your inhalers correctly, avoiding triggers, and still having flare-ups, your care team may need to adjust your maintenance medications (the medicines you take every day to prevent symptoms, unlike rescue inhalers used for immediate relief).

Common Inhaler Types:

  • LAMA (Long-Acting Muscarinic Antagonist): A bronchodilator that relaxes airway muscles.
  • LABA (Long-Acting Beta-Agonist): Another type of bronchodilator that keeps airways open.
  • ICS (Inhaled Corticosteroid): A medicine that reduces inflammation in the airways.

Optimizing Bronchodilators:
The foundation of COPD treatment is long-acting bronchodilators. If you are having flare-ups on a single daily inhaler, stepping up to a dual combination (LABA/LAMA) is a standard next step [9] [29].

Adding Inhaled Corticosteroids (ICS):
If dual bronchodilators aren’t enough, your doctor may suggest “triple therapy” by adding an ICS. This is highly beneficial if you have a history of asthma [30]. Your doctor will also look at your blood eosinophil count (a type of white blood cell). Rather than a strict cutoff, this is a gradient: counts above 300 cells/µL strongly predict you will benefit from an ICS, while counts below 100 suggest little benefit [30] [31]. This benefit must be carefully weighed against side effects, including an increased risk of pneumonia, oral thrush, bruising, and hoarseness [32].

Specialized Add-On Therapies:
For patients who continue to have frequent, severe flare-ups despite optimized inhaler therapy, specialists may consider targeted add-on treatments. These are not rescue medicines for sudden attacks.

  • Roflumilast: This daily pill reduces inflammation. It is generally reserved for patients with severe airflow obstruction, chronic bronchitis (a daily cough with phlegm), and a history of hospitalizations for COPD [2] [33] [34]. Because it can cause severe weight loss, diarrhea, sleep issues, and psychiatric side effects (including depression and suicidal thoughts), careful patient selection and monitoring are required [35] [36].
  • Prophylactic Macrolides (e.g., Azithromycin): Taking a low dose of this antibiotic regularly (daily or a few times a week) can reduce the number of flare-ups in selected high-risk patients [37] [1]. This is typically a specialist decision for a defined period of time (e.g., one year). It requires baseline and ongoing monitoring for heart rhythm abnormalities (measured by QTc on an ECG), hearing loss, liver function, and antibiotic resistance [1] [38] [39] [40]. It may be less effective in current smokers.

Common questions in this guide

Why do I keep having COPD exacerbations?
Repeated COPD flare-ups can result from incorrect inhaler technique, missed daily doses, smoking, air pollution, or respiratory infections. Heart failure, asthma features, bronchiectasis, sleep apnea, or another problem can also look like a COPD flare-up or make it worse, so frequent episodes deserve a medical review. Having exacerbations does not necessarily mean you caused them.
What can I do every day to prevent COPD flare-ups?
Use maintenance inhalers exactly as prescribed and ask a pharmacist or clinician to check your device technique. Avoid smoke and irritating fumes, monitor air-quality alerts, stop smoking if you smoke, stay current on recommended vaccines, and follow a written action plan. Pulmonary rehabilitation may also improve strength and help you respond to symptoms.
Could something besides COPD be causing my repeated breathlessness?
Yes. Heart failure, asthma features, bronchiectasis, untreated obstructive sleep apnea, and a blood clot in the lung can cause or worsen breathlessness and may be mistaken for a COPD exacerbation. Unusually sudden, severe, or unexplained episodes should be evaluated promptly.
When should a COPD flare-up be treated as an emergency?
Seek emergency care for severe breathlessness at rest, inability to speak in full sentences, blue or gray lips or fingers, new confusion, extreme drowsiness, chest pain, or symptoms that rapidly worsen and do not improve with your prescribed rescue inhaler. Do not wait for a routine appointment when these signs occur.
How do doctors decide whether to add an inhaled steroid?
A clinician considers your exacerbation history, whether you have asthma features, and your blood eosinophil count when deciding whether an inhaled corticosteroid is likely to help. Adding one can reduce flare-ups for selected patients, but it can also raise the risk of pneumonia, oral thrush, bruising, and hoarseness. Do not start or stop it without medical guidance.
What does pulmonary rehabilitation do for people with frequent COPD flare-ups?
Pulmonary rehabilitation combines supervised exercise, education, and emotional support to improve strength and breathing-related confidence. It can help people recover after a severe exacerbation and reduce the impact of future flare-ups. Ask your clinician when it is safe and appropriate to begin.

Related questions

When Are Oral Steroids Used for COPD? Side Effects Explained What Does a Low DLCO Indicate in COPD? Causes Explained When Are Antibiotics Needed for a COPD Exacerbation? What Does FEV1 Percent Predicted Mean for COPD Prognosis? What Is a Mild, Moderate, or Severe COPD Exacerbation?
Show more
How Often Should Spirometry Be Repeated for COPD Monitoring? Is COPD Reversible? Can Treatment Restore Lung Function? Should COPD Patients Get Low-Dose CT Lung Cancer Screening? What Does a Low Alpha-1 Antitrypsin Test Mean for COPD? How Is the BODE Index Calculated and Interpreted in COPD? How Is a Severe COPD Exacerbation Treated in the Hospital? Can You Get COPD If You Have Never Smoked? Causes Explained What Happens If I Have Asthma and COPD Together? Explained Why Can COPD Be GOLD Grade 2 and Still Be Group E? Can Borderline Spirometry Confirm COPD? When to Repeat? What Are COPD-Related PH and Cor Pulmonale Symptoms? What Should a Written COPD Exacerbation Action Plan Include? Do I Need a Chest CT, Chest X-ray, or DLCO Test for COPD? What Comorbidities Should COPD Checkups Screen For?

Get notified when new evidence is published on chronic obstructive pulmonary disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (40)
  1. 1

    Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).

    Herath SC, Normansell R, Maisey S, Poole P

    The Cochrane database of systematic reviews 2018; (10()):CD009764 doi:10.1002/14651858.CD009764.pub3.

    PMID: 30376188
  2. 2

    Cost-effectiveness of roflumilast as an add-on to triple inhaled therapy vs triple inhaled therapy in patients with severe and very severe COPD associated with chronic bronchitis in the UK.

    Kiff C, Ruiz S, Varol N, et al.

    International journal of chronic obstructive pulmonary disease 2018; (13()):2707-2720 doi:10.2147/COPD.S167730.

    PMID: 30214188
  3. 3

    Unstable exacerbating COPD: Unaddressed modifiable risk factors or unstable despite optimised care.

    Nielsen SB, Mistarz N, Lapperre T, et al.

    Respiratory medicine 2026; (259()):108893 doi:10.1016/j.rmed.2026.108893.

    PMID: 42155782
  4. 4

    Advances in chronic obstructive pulmonary disease: management of exacerbations.

    Jeyachandran V, Hurst JR

    British journal of hospital medicine (London, England : 2005) 2022; (83(7)):1-7 doi:10.12968/hmed.2022.0275.

    PMID: 35938767
  5. 5

    Risk factors of chronic obstructive pulmonary disease exacerbations.

    Hogea SP, Tudorache E, Fildan AP, et al.

    The clinical respiratory journal 2020; (14(3)):183-197 doi:10.1111/crj.13129.

    PMID: 31814260
  6. 6

    New Perspectives in COPD Management.

    Yawn B

    The Journal of family practice 2021; (70(6S)):S29-S34 doi:10.12788/jfp.0220.

    PMID: 34432621
  7. 7

    Predictors of Suboptimal Peak Inspiratory Flow in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Clinical Practice.

    Trushenko NV, Lavginova BB, Chikina SY, et al.

    Tuberculosis and respiratory diseases 2025; (88(3)):516-525 doi:10.4046/trd.2024.0154.

    PMID: 40049214
  8. 8

    COPD Management in Community Pharmacy Results in Improved Inhaler Use, Immunization Rate, COPD Action Plan Ownership, COPD Knowledge, and Reductions in Exacerbation Rates.

    Fathima M, Bawa Z, Mitchell B, et al.

    International journal of chronic obstructive pulmonary disease 2021; (16()):519-533 doi:10.2147/COPD.S288792.

    PMID: 33688177
  9. 9

    [COPD - what has changed in GOLD 2023 and is relevant for clinical practice?]

    Klemmer A, Alter P, Vogelmeier CF

    Deutsche medizinische Wochenschrift (1946) 2023; (148(12)):780-787 doi:10.1055/a-1997-1375.

    PMID: 37257481
  10. 10

    COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update.

    Yang IA, Brown JL, George J, et al.

    The Medical journal of Australia 2017; (207(10)):436-442 doi:10.5694/mja17.00686.

    PMID: 29129177
  11. 11

    Exacerbations of COPD.

    Viniol C, Vogelmeier CF

    European respiratory review : an official journal of the European Respiratory Society 2018; (27(147)) doi:10.1183/16000617.0103-2017.

    PMID: 29540496
  12. 12

    Short-term air pollution exposure and exacerbation events in mild to moderate COPD: a case-crossover study within the CanCOLD cohort.

    Ross BA, Doiron D, Benedetti A, et al.

    Thorax 2023; (78(10)):974-982 doi:10.1136/thorax-2022-219619.

    PMID: 37147124
  13. 13

    Fine particulate matter in acute exacerbation of COPD.

    Ni L, Chuang CC, Zuo L

    Frontiers in physiology 2015; (6()):294 doi:10.3389/fphys.2015.00294.

    PMID: 26557095
  14. 14

    Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations.

    Ritchie AI, Wedzicha JA

    Clinics in chest medicine 2020; (41(3)):421-438 doi:10.1016/j.ccm.2020.06.007.

    PMID: 32800196
  15. 15

    Seasonal influenza vaccination in patients with COPD: a systematic literature review.

    Bekkat-Berkani R, Wilkinson T, Buchy P, et al.

    BMC pulmonary medicine 2017; (17(1)):79 doi:10.1186/s12890-017-0420-8.

    PMID: 28468650
  16. 16

    Bacterial Vaccinations in Patients with Chronic Obstructive Pulmonary Disease.

    Paróczai D, Burian K, Bikov A

    Vaccines 2024; (12(2)) doi:10.3390/vaccines12020213.

    PMID: 38400196
  17. 17

    Effects of Vaccination on Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Cohort Study.

    Kim SH, Lee H, Kim MJ, et al.

    Tuberculosis and respiratory diseases 2025; (88(3)):526-534 doi:10.4046/trd.2024.0182.

    PMID: 40015289
  18. 18

    Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.

    Wedzicha JA, Miravitlles M, Hurst JR, et al.

    The European respiratory journal 2017; (49(3)) doi:10.1183/13993003.00791-2016.

    PMID: 28298398
  19. 19

    Management of chronic obstructive pulmonary disease beyond the lungs.

    Vanfleteren LEGW, Spruit MA, Wouters EFM, Franssen FME

    The Lancet. Respiratory medicine 2016; (4(11)):911-924 doi:10.1016/S2213-2600(16)00097-7.

    PMID: 27264777
  20. 20

    Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease.

    Lenferink A, Brusse-Keizer M, van der Valk PD, et al.

    The Cochrane database of systematic reviews 2017; (8()):CD011682 doi:10.1002/14651858.CD011682.pub2.

    PMID: 28777450
  21. 21

    A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease.

    , Bhatt SP, Abadi E, et al.

    JAMA 2025; (333(24)):2164-2175 doi:10.1001/jama.2025.7358.

    PMID: 40382791
  22. 22

    Heart failure and chronic obstructive pulmonary disease. A combination not to be underestimated.

    Magrì D, Fiori E, Agostoni P, et al.

    Heart failure reviews 2025; (30(6)):1525-1538 doi:10.1007/s10741-025-10566-3.

    PMID: 41053405
  23. 23

    B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review.

    Hawkins NM, Khosla A, Virani SA, et al.

    BMC pulmonary medicine 2017; (17(1)):11 doi:10.1186/s12890-016-0345-7.

    PMID: 28073350
  24. 24

    Differences in prevalence of asthma-COPD overlap according to different criteria.

    Song JH, Lee CH, Kim DK, et al.

    Medicine 2018; (97(36)):e12049 doi:10.1097/MD.0000000000012049.

    PMID: 30200085
  25. 25

    COTE and Pulmonary Comorbidities Predict Moderate-to-Severe Acute Exacerbation and Hospitalization in COPD.

    Chen Q, Wang X, Yao X, et al.

    International journal of chronic obstructive pulmonary disease 2025; (20()):1893-1913 doi:10.2147/COPD.S518218.

    PMID: 40524721
  26. 26

    Understanding COPD-overlap syndromes.

    Poh TY, Mac Aogáin M, Chan AK, et al.

    Expert review of respiratory medicine 2017; (11(4)):285-298 doi:10.1080/17476348.2017.1305895.

    PMID: 28282995
  27. 27

    Apnea-Hypopnea Index in Chronic Obstructive Pulmonary Disease Exacerbation Requiring Noninvasive Mechanical Ventilation with Average Volume-Assured Pressure Support.

    Briones-Claudett KH, Romero Lopez A, Briones-Claudett MH, et al.

    Critical care research and practice 2021; (2021()):7793657 doi:10.1155/2021/7793657.

    PMID: 34873453
  28. 28

    Pulmonary embolism work-up in chronic obstructive pulmonary disease exacerbations: what is the best strategy for clinicians?

    Jiménez D, Bertoletti L, Bikdeli B

    Current opinion in pulmonary medicine 2025; (31(2)):175-181 doi:10.1097/MCP.0000000000001130.

    PMID: 39469884
  29. 29

    LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations.

    Miravitlles M, Kawayama T, Dreher M

    Journal of clinical medicine 2022; (11(22)) doi:10.3390/jcm11226623.

    PMID: 36431099
  30. 30

    Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis.

    Cazzola M, Rogliani P, Calzetta L, Matera MG

    The European respiratory journal 2018; (52(6)) doi:10.1183/13993003.01586-2018.

    PMID: 30309975
  31. 31

    Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis.

    Harries TH, Rowland V, Corrigan CJ, et al.

    Respiratory research 2020; (21(1)):3 doi:10.1186/s12931-019-1268-7.

    PMID: 31900184
  32. 32

    Triple versus dual inhaler therapy in moderate-to-severe COPD: A systematic review and meta-analysis of randomized controlled trials.

    Zayed Y, Barbarawi M, Kheiri B, et al.

    The clinical respiratory journal 2019; (13(7)):413-428 doi:10.1111/crj.13026.

    PMID: 30947394
  33. 33

    Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

    Martinez FJ, Calverley PM, Goehring UM, et al.

    Lancet (London, England) 2015; (385(9971)):857-66.

    PMID: 25684586
  34. 34

    Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials.

    Martinez FJ, Rabe KF, Calverley PMA, et al.

    American journal of respiratory and critical care medicine 2018; (198(10)):1268-1278 doi:10.1164/rccm.201712-2493OC.

    PMID: 29763572
  35. 35

    Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease.

    Janjua S, Fortescue R, Poole P

    The Cochrane database of systematic reviews 2020; (5()):CD002309 doi:10.1002/14651858.CD002309.pub6.

    PMID: 32356609
  36. 36

    Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease.

    Kim KH, Kang HS, Kim JS, et al.

    International journal of chronic obstructive pulmonary disease 2017; (12()):3449-3456 doi:10.2147/COPD.S143967.

    PMID: 29270006
  37. 37

    Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators.

    Gulati S, Wells JM

    Drugs 2017; (77(6)):651-670 doi:10.1007/s40265-017-0713-5.

    PMID: 28255962
  38. 38

    Macrolide prescribing and preemptive electrocardiograms in asthma, COPD, ACO, and general population: a drug-utilization study.

    Pera V, Lepouttre H, Barboza C, et al.

    The Journal of asthma : official journal of the Association for the Care of Asthma 2025; 1-14 doi:10.1080/02770903.2025.2589788.

    PMID: 41250618
  39. 39

    Clinical and Safety Outcomes of Long-Term Azithromycin Therapy in Severe COPD Beyond the First Year of Treatment.

    Pomares X, Montón C, Bullich M, et al.

    Chest 2018; (153(5)):1125-1133 doi:10.1016/j.chest.2018.01.044.

    PMID: 29427576
  40. 40

    Effects of prophylactic antibiotics on patients with stable COPD: a systematic review and meta-analysis of randomized controlled trials.

    Wang Y, Zijp TR, Bahar MA, et al.

    The Journal of antimicrobial chemotherapy 2018; (73(12)):3231-3243 doi:10.1093/jac/dky326.

    PMID: 30189002

This page is for informational purposes only and does not constitute medical advice about recurrent COPD exacerbations. Do not change inhalers or start preventive medicines without guidance from your clinician.